gabexate has been researched along with Inhalation Injury, Smoke in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niehaus, GD | 1 |
| Kimura, R | 1 |
| Traber, LD | 1 |
| Herndon, DN | 1 |
| Flynn, JT | 1 |
| Traber, DL | 1 |
1 other study available for gabexate and Inhalation Injury, Smoke
| Article | Year |
|---|---|
Administration of a synthetic antiprotease reduces smoke-induced lung injury.
Topics: alpha-Macroglobulins; Animals; Endopeptidases; Female; Gabexate; Guanidines; Lung Injury; Neutrophil | 1990 |